Key result
Facilitated percutaneous coronary intervention resulted in no significant differences in peak cardiac enzymes, 30-day mortality, or hemorrhagic complications across age groups from 40 to 80 years.
Cohort (n=162)
Yes
p-value: p=>0.05
Facilitated PCI using mutant t-PA followed by emergency angiography showed similar efficacy and safety across different age groups up to 80 years in Japanese patients with acute myocardial infarction.
May support facilitated PCI across ages 40-80 in AMI; hypothesis-generating, leaves open need for randomized confirmation.
BACKGROUND: The purpose of the present study was to evaluate the efficacy and safety of facilitated percutaneous coronary intervention (PCI) in comparing young and elderly patients with acute myocardial infarction. METHODS AND RESULTS: The present study enrolled 168 initial myocardial infarction patients within 12 h of the symptom onset between 40 and 80 years of age who were indicated on the fibrinolysis and subsequent transluminal (FAST-3) trial. The patients were divided into 4 groups according to their age, peak creatine kinase (CK), peak CK-MB and peak troponin T (Tn-T) levels, and cardiac function were compared between the 4 groups. There were no differences between the 4 groups in terms of the time from arrival at the emergency room (ER) to the achievement of TIMI-3 patency. There were also no significant differences between the 4 groups in terms of the peak CK, peak CK-MB or peak Tn-T levels. Furthermore, there were no significant differences between the 4 groups in terms of the mortality rate or the incidence of hemorrhagic complications at 30 days. CONCLUSIONS: Facilitated PCI is considered to have an important potential role in the treatment of myocardial infarction in Japan, in which the age of the population is steadily increasing.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2004) conducted a cohort in Acute Myocardial Infarction (n=162). Facilitated percutaneous coronary intervention vs. Age groups (40-49, 50-59, 60-69, 70-79 years) was evaluated on Extent of myocardial damage (peak CK, CK-MB, and troponin T levels) (p=>0.05). Facilitated percutaneous coronary intervention resulted in no significant differences in peak cardiac enzymes, 30-day mortality, or hemorrhagic complications across age groups from 40 to 80 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: